TY - JOUR
T1 - reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid
AU - Sica, Simona
PY - 2019
Y1 - 2019
N2 - cute promyelocytic leukemia (APL) is a variant of AML characterized by t (15; 17). The discovery of the molecular pathogenesis has led to the first targeted therapy for acute leukemia: all-trans retinoic acid (ATRA). ATRA is usually associated to anthracycline-based chemotherapy obtaining high response rates, but some potential longterm sequelae are described [1]. The introduction of arsenic trioxide (ATO)[2] and ATRA was compared to standard chemotherapy in a pivotal trial with excellent results both in terms of complete
AB - cute promyelocytic leukemia (APL) is a variant of AML characterized by t (15; 17). The discovery of the molecular pathogenesis has led to the first targeted therapy for acute leukemia: all-trans retinoic acid (ATRA). ATRA is usually associated to anthracycline-based chemotherapy obtaining high response rates, but some potential longterm sequelae are described [1]. The introduction of arsenic trioxide (ATO)[2] and ATRA was compared to standard chemotherapy in a pivotal trial with excellent results both in terms of complete
KW - reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid
KW - reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxite plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid
UR - http://hdl.handle.net/10807/169715
M3 - Article
SN - 1042-8194
SP - 1328
EP - 1330
JO - LEUKEMIA & LYMPHOMA
JF - LEUKEMIA & LYMPHOMA
ER -